Biogen Idec Inc (BIIB) 315.96 $BIIB
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Biogen, Inc.
PR Newswire - Tue Jul 28, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Biogen, Inc. ("Biogen" or the "Company"
(NasdaqGS: BIIB -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
BIIB: 315.96 (+6.53)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 159.44 (-0.05), BIIB: 315.96 (+6.53), LGND: 106.77 (+4.22), REGN: 558.99 (+18.96), EXEL: 5.55 (+0.11)
Watching Twitter for Moves at Teva and Biogen
at The Street - Tue Jul 28, 7:28AM CDT
Twitter sentiment predicts the big moves in two healthcare stocks-NYMX and BIIB.
BIIB: 315.96 (+6.53), TEVA: 71.15 (-0.85)
3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 315.96 (+6.53), GILD: 113.15 (+2.61), CELG: 135.83 (+3.27)
Biogen & the Parkinson's Institute and Clinical Center reports strategic alliance to form novel tools and programmes to accelerate research and the development of new treatments in Parkinson's disease
M2 - Tue Jul 28, 5:33AM CDT
Biotechnology company Biogen (NasdaqGS:BIIB) revealed on Monday the establishment of a strategic alliance with the Parkinson's Institute and Clinical Center, to enhance the understanding of the underlying biology of Parkinson's disease (PD) and the creation of novel tools and programmes that could accelerate research and the development of new PD treatments.
BIIB: 315.96 (+6.53)
'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
at The Street - Tue Jul 28, 5:00AM CDT
Cramer thinks Cerus is a nice speculative stock, says to wait on ConocoPhillips and to buy 3M at $142.
CERS: 5.37 (+0.17), MMM: 151.44 (+2.73), BIIB: 315.96 (+6.53), ISIS: 54.59 (+0.91), MDSO: 54.30 (+1.47), COP: 52.52 (+1.87), SNDK: 60.86 (-0.30)
Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs
at The Street - Mon Jul 27, 7:16PM CDT
Cramer says this is the thinnest market we've seen in ages, and that's not good.
CERS: 5.37 (+0.17), MMM: 151.44 (+2.73), AMZN: 524.28 (-7.13), BIIB: 315.96 (+6.53), MDLZ: 42.69 (+0.66), EA: 71.91 (+0.69), SNA: 160.14 (+3.05), NKE: 113.73 (+2.00), MDSO: 54.30 (+1.47), FB: 94.78 (+0.61), FCX: 12.39 (+1.02), COP: 52.52 (+1.87), DIS: 118.55 (+0.30), NFLX: 107.22 (+0.79), ISIS: 54.59 (+0.91), QLIK: 40.50 (+0.56), KHC: 78.34 (+0.96), GOOGL: 656.77 (-1.50), ULTA: 165.94 (-0.45), CMCSA: 62.08 (+0.97), GIS: 57.38 (+0.42), SNDK: 60.86 (-0.30)
Which Big-Cap Stocks Are Defying Market Pressure?
at Investor's Business Daily - Mon Jul 27, 5:46PM CDT
When an uptrend comes under pressure, some stocks show action worthy of a drumroll, while others inspire eye rolls. The recent trouble for the uptrend started after the July 20 close. The S&P 500 suffered four distribution days in a row through...
BIIB: 315.96 (+6.53), MNST: 149.91 (+1.15), VRX: 257.73 (+0.43), GILD: 113.15 (+2.61), CMG: 729.48 (-1.96)
5 Things Biogen's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 27, 5:00PM CDT
Biogen held a conference call in conjunction with its second-quarter earnings last week. Here are five things that management said that investors should be paying attention to. "We had expected to see a reacceleration of Tecfidera this quarter,...
BIIB: 315.96 (+6.53)
Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash
at The Street - Mon Jul 27, 3:30PM CDT
People are "max negative" on Twitter ahead of its earnings report Tuesday, which Jim Cramer doesn't see as unjustified -- at least, in the short term.
AGN: 337.68 (+10.70), BIIB: 315.96 (+6.53), GILD: 113.15 (+2.61), TEVA: 71.15 (-0.85), TWTR: 35.82 (+1.12)
Is the U.S. Bull Market Starting to Lose Its Luster?
at The Street - Mon Jul 27, 2:04PM CDT
CNBC’s ‘Fast Money’ traders take a closer look at U.S. stocks, as the selloff in China weighs on the market.
BIIB: 315.96 (+6.53), PRGO: 190.65 (-2.95), XOM: 82.14 (+2.88), MYL: 55.70 (-0.67), BMY: 64.45 (+0.15), AGN: 337.68 (+10.70), ISRG: 540.82 (-3.33), SBUX: 57.11 (+0.13), HCA: 92.03 (unch), IBM: 159.50 (+0.43), GM: 31.26 (+0.21), TEVA: 71.15 (-0.85), SPLK: 70.49 (-0.11), REGN: 558.99 (+18.96), NVS: 102.60 (+1.06)
4 Stocks Breaking Out on Big Volume
at The Street - Mon Jul 27, 1:30PM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
BIIB: 315.96 (+6.53), TERP: 31.13 (-0.20), WAB: 98.89 (+0.96), ENTA: 48.48 (+1.01)
Cramer -- Intel's a Few Bucks Away From a Buy, but PayPal Is One Right Now
at The Street - Mon Jul 27, 11:32AM CDT
Tech stocks were on the minds of viewers Monday morning when they posed their questions to TheStreet's Jim Cramer, including Intel, T-Mobile and PayPal.
BIIB: 315.96 (+6.53), GILD: 113.15 (+2.61), ALTR: 49.16 (+0.24), XON: 60.23 (+5.66), PYPL: 37.52 (+1.13), TMUS: 37.00 (+0.50), TWTR: 35.82 (+1.12), INTC: 28.87 (+0.52)
Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
at The Street - Mon Jul 27, 10:38AM CDT
Jim Cramer is not hungry for GrubHub and says Biogen is turning into a battle royale for biotech investors.
BIIB: 315.96 (+6.53), GRUB: 32.43 (+1.42), XBI: 259.27 (+7.49), IBB: 382.73 (+9.15), REGN: 558.99 (+18.96), CELG: 135.83 (+3.27)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.44 (-0.05), BIIB: 315.96 (+6.53), LGND: 106.77 (+4.22), AMGN: 173.02 (+7.48), REGN: 558.99 (+18.96), EXEL: 5.55 (+0.11), CELG: 135.83 (+3.27)
3 Signs That the Healthcare Stock Bubble Might Have Just Popped
George Budwell, The Motley Fool - Motley Fool - Mon Jul 27, 9:42AM CDT
Over the past five years or so, healthcare stocks have been absolutely trouncing the broader markets, leading many to call this unprecedented bull run a "bubble." A deeper look, though, reveals that most of this hypergrowth in the healthcare...
BIIB: 315.96 (+6.53), ILMN: 218.14 (+0.87), ABBV: 70.72 (+1.38)
3 Great Values to Buy on the Nasdaq - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:42AM CDT
Since the long term holds good for stocks listed on the Nasdaq, it will be a prudent idea to invest in value stocks despite short-term volatility.
SGYP: 8.19 (unch), AMZN: 524.28 (-7.13), BIIB: 315.96 (+6.53), TTMI: 9.19 (+0.05), FB: 94.78 (+0.61), NFLX: 107.22 (+0.79), YHOO: 37.64 (-0.19), QCOM: 63.28 (+1.30), GOOGL: 656.77 (-1.50), ANAC: 152.73 (+8.43), MSFT: 45.36 (+0.01), TECD: 56.51 (+0.99), AAPL: 123.33 (+0.56)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 159.44 (-0.05), BIIB: 315.96 (+6.53), NBIX: 52.07 (+2.73), ISIS: 54.59 (+0.91), SRPT: 32.36 (+0.36), RCPT: 227.79 (+0.70)
Biogen (BIIB) Stock Rebounding Following Bernstein Upgrade
at The Street - Mon Jul 27, 9:30AM CDT
Biogen (BIIB) stock is up after analysts at Bernstein raised their rating to 'outperform' from 'market perform' this morning.
BIIB: 315.96 (+6.53)
Stock Market News for July 27, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Declines in biotech and commodity related stocks dragged benchmarks down to on the red on Friday
BIIB: 315.96 (+6.53), AMZN: 524.28 (-7.13), MON: 100.82 (-0.64), COP: 52.52 (+1.87), AMGN: 173.02 (+7.48), XOM: 82.14 (+2.88), SLB: 82.67 (+0.91), CELG: 135.83 (+3.27), RIG: 13.98 (+0.87), GILD: 113.15 (+2.61), DD: 56.07 (-0.66), PX: 114.71 (+2.89), CVX: 92.08 (+2.94), DOW: 46.71 (+1.08), REGN: 558.99 (+18.96)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Biogen, Inc.
PR Newswire - Tue Jul 28, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Biogen, Inc. ("Biogen" or the "Company"
(NasdaqGS: BIIB -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. BIIB: 315.96 (+6.53)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 159.44 (-0.05), BIIB: 315.96 (+6.53), LGND: 106.77 (+4.22), REGN: 558.99 (+18.96), EXEL: 5.55 (+0.11)
Watching Twitter for Moves at Teva and Biogen
at The Street - Tue Jul 28, 7:28AM CDT
Twitter sentiment predicts the big moves in two healthcare stocks-NYMX and BIIB.
BIIB: 315.96 (+6.53), TEVA: 71.15 (-0.85)
3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 315.96 (+6.53), GILD: 113.15 (+2.61), CELG: 135.83 (+3.27)
Biogen & the Parkinson's Institute and Clinical Center reports strategic alliance to form novel tools and programmes to accelerate research and the development of new treatments in Parkinson's disease
M2 - Tue Jul 28, 5:33AM CDT
Biotechnology company Biogen (NasdaqGS:BIIB) revealed on Monday the establishment of a strategic alliance with the Parkinson's Institute and Clinical Center, to enhance the understanding of the underlying biology of Parkinson's disease (PD) and the creation of novel tools and programmes that could accelerate research and the development of new PD treatments.
BIIB: 315.96 (+6.53)
'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
at The Street - Tue Jul 28, 5:00AM CDT
Cramer thinks Cerus is a nice speculative stock, says to wait on ConocoPhillips and to buy 3M at $142.
CERS: 5.37 (+0.17), MMM: 151.44 (+2.73), BIIB: 315.96 (+6.53), ISIS: 54.59 (+0.91), MDSO: 54.30 (+1.47), COP: 52.52 (+1.87), SNDK: 60.86 (-0.30)
Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs
at The Street - Mon Jul 27, 7:16PM CDT
Cramer says this is the thinnest market we've seen in ages, and that's not good.
CERS: 5.37 (+0.17), MMM: 151.44 (+2.73), AMZN: 524.28 (-7.13), BIIB: 315.96 (+6.53), MDLZ: 42.69 (+0.66), EA: 71.91 (+0.69), SNA: 160.14 (+3.05), NKE: 113.73 (+2.00), MDSO: 54.30 (+1.47), FB: 94.78 (+0.61), FCX: 12.39 (+1.02), COP: 52.52 (+1.87), DIS: 118.55 (+0.30), NFLX: 107.22 (+0.79), ISIS: 54.59 (+0.91), QLIK: 40.50 (+0.56), KHC: 78.34 (+0.96), GOOGL: 656.77 (-1.50), ULTA: 165.94 (-0.45), CMCSA: 62.08 (+0.97), GIS: 57.38 (+0.42), SNDK: 60.86 (-0.30)
Which Big-Cap Stocks Are Defying Market Pressure?
at Investor's Business Daily - Mon Jul 27, 5:46PM CDT
When an uptrend comes under pressure, some stocks show action worthy of a drumroll, while others inspire eye rolls. The recent trouble for the uptrend started after the July 20 close. The S&P 500 suffered four distribution days in a row through...
BIIB: 315.96 (+6.53), MNST: 149.91 (+1.15), VRX: 257.73 (+0.43), GILD: 113.15 (+2.61), CMG: 729.48 (-1.96)
5 Things Biogen's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 27, 5:00PM CDT
Biogen held a conference call in conjunction with its second-quarter earnings last week. Here are five things that management said that investors should be paying attention to. "We had expected to see a reacceleration of Tecfidera this quarter,...
BIIB: 315.96 (+6.53)
Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash
at The Street - Mon Jul 27, 3:30PM CDT
People are "max negative" on Twitter ahead of its earnings report Tuesday, which Jim Cramer doesn't see as unjustified -- at least, in the short term.
AGN: 337.68 (+10.70), BIIB: 315.96 (+6.53), GILD: 113.15 (+2.61), TEVA: 71.15 (-0.85), TWTR: 35.82 (+1.12)
Is the U.S. Bull Market Starting to Lose Its Luster?
at The Street - Mon Jul 27, 2:04PM CDT
CNBC’s ‘Fast Money’ traders take a closer look at U.S. stocks, as the selloff in China weighs on the market.
BIIB: 315.96 (+6.53), PRGO: 190.65 (-2.95), XOM: 82.14 (+2.88), MYL: 55.70 (-0.67), BMY: 64.45 (+0.15), AGN: 337.68 (+10.70), ISRG: 540.82 (-3.33), SBUX: 57.11 (+0.13), HCA: 92.03 (unch), IBM: 159.50 (+0.43), GM: 31.26 (+0.21), TEVA: 71.15 (-0.85), SPLK: 70.49 (-0.11), REGN: 558.99 (+18.96), NVS: 102.60 (+1.06)
4 Stocks Breaking Out on Big Volume
at The Street - Mon Jul 27, 1:30PM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
BIIB: 315.96 (+6.53), TERP: 31.13 (-0.20), WAB: 98.89 (+0.96), ENTA: 48.48 (+1.01)
Cramer -- Intel's a Few Bucks Away From a Buy, but PayPal Is One Right Now
at The Street - Mon Jul 27, 11:32AM CDT
Tech stocks were on the minds of viewers Monday morning when they posed their questions to TheStreet's Jim Cramer, including Intel, T-Mobile and PayPal.
BIIB: 315.96 (+6.53), GILD: 113.15 (+2.61), ALTR: 49.16 (+0.24), XON: 60.23 (+5.66), PYPL: 37.52 (+1.13), TMUS: 37.00 (+0.50), TWTR: 35.82 (+1.12), INTC: 28.87 (+0.52)
Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
at The Street - Mon Jul 27, 10:38AM CDT
Jim Cramer is not hungry for GrubHub and says Biogen is turning into a battle royale for biotech investors.
BIIB: 315.96 (+6.53), GRUB: 32.43 (+1.42), XBI: 259.27 (+7.49), IBB: 382.73 (+9.15), REGN: 558.99 (+18.96), CELG: 135.83 (+3.27)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 159.44 (-0.05), BIIB: 315.96 (+6.53), LGND: 106.77 (+4.22), AMGN: 173.02 (+7.48), REGN: 558.99 (+18.96), EXEL: 5.55 (+0.11), CELG: 135.83 (+3.27)
3 Signs That the Healthcare Stock Bubble Might Have Just Popped
George Budwell, The Motley Fool - Motley Fool - Mon Jul 27, 9:42AM CDT
Over the past five years or so, healthcare stocks have been absolutely trouncing the broader markets, leading many to call this unprecedented bull run a "bubble." A deeper look, though, reveals that most of this hypergrowth in the healthcare...
BIIB: 315.96 (+6.53), ILMN: 218.14 (+0.87), ABBV: 70.72 (+1.38)
3 Great Values to Buy on the Nasdaq - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:42AM CDT
Since the long term holds good for stocks listed on the Nasdaq, it will be a prudent idea to invest in value stocks despite short-term volatility.
SGYP: 8.19 (unch), AMZN: 524.28 (-7.13), BIIB: 315.96 (+6.53), TTMI: 9.19 (+0.05), FB: 94.78 (+0.61), NFLX: 107.22 (+0.79), YHOO: 37.64 (-0.19), QCOM: 63.28 (+1.30), GOOGL: 656.77 (-1.50), ANAC: 152.73 (+8.43), MSFT: 45.36 (+0.01), TECD: 56.51 (+0.99), AAPL: 123.33 (+0.56)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 159.44 (-0.05), BIIB: 315.96 (+6.53), NBIX: 52.07 (+2.73), ISIS: 54.59 (+0.91), SRPT: 32.36 (+0.36), RCPT: 227.79 (+0.70)
Biogen (BIIB) Stock Rebounding Following Bernstein Upgrade
at The Street - Mon Jul 27, 9:30AM CDT
Biogen (BIIB) stock is up after analysts at Bernstein raised their rating to 'outperform' from 'market perform' this morning.
BIIB: 315.96 (+6.53)
Stock Market News for July 27, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Declines in biotech and commodity related stocks dragged benchmarks down to on the red on Friday
BIIB: 315.96 (+6.53), AMZN: 524.28 (-7.13), MON: 100.82 (-0.64), COP: 52.52 (+1.87), AMGN: 173.02 (+7.48), XOM: 82.14 (+2.88), SLB: 82.67 (+0.91), CELG: 135.83 (+3.27), RIG: 13.98 (+0.87), GILD: 113.15 (+2.61), DD: 56.07 (-0.66), PX: 114.71 (+2.89), CVX: 92.08 (+2.94), DOW: 46.71 (+1.08), REGN: 558.99 (+18.96)
